Catalog: | C-FC-2829A |
Product Type: | FCM Antibody |
Size: | 25 Tests/100 Tests |
Concentration: | 2 μl/Test, 0.1 mg/ml |
Reactivity: | Human |
Specificity: | Human B7-H3 |
Analysis mode: | FCM |
Host: | Mouse |
Clonality: | Monoclonal |
Isotype: | IgG2b |
Alternate names: | CD276 molecule |
Form: | Liquid |
Shipping: | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Storage: | This antibody can be stored at 2℃-8℃ for twelve months without detectable loss of activity. Protected from prolonged exposure to light. Do not freeze ! Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal. |
Purification method: | Protein A |
Conjugation: | APC |
Immunogen: | Recombinant Human B7-H3 / CD276 protein |
Buffer: | Aqueous solution containing 0.5% BSA and 0.09% sodium azide |
Application: | Cancer Drug Targets |
B7-H3 is a member of the B7 family of immune regulatory ligands that is thought to attenuate peripheral immune responses through co-inhibition. It plays an important role in adaptive immune responses, and was shown to either promote or inhibit T-cell responses in various experimental systems. B7-H3 may play an important role in muscle-immune interactions, providing further evidence of the active role of muscle cells in local immunoregulatory processes. B7-H3 is a novel protein structurally related to the B7 family of ligands by the presence of a single set of immunoglobulin-V-like and immunoglobulin-C-like (VC) domains. Previous studies have correlated its overexpression with poor prognosis and decreased tumor-infiltrating lymphocytes in various carcinomas including uterine endometrioid carcinomas, and mounting evidence supports an immuno-inhibitory role in ovarian cancer prognosis. Recently, B7-H3 expression has been reported in several human cancers indicating an additional function of B7-H3 as a regulator of antitumor immunity.
Copyright © 2024 Creative Biogene. All rights reserved.